Mereo BioPharma (MREO) FCF Margin (2023 - 2025)
Mereo BioPharma's (MREO) quarterly FCF Margin came in at 1530.2% in Q2 2025, down 125.39% quarter-over-quarter from 678.9% in Q4 2023.
Powered by 
Analysis
Mereo BioPharma (MREO) FCF Margin (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported FCF Margin for 2 consecutive years, with 1530.2% the latest figure, recorded in Q2 2025.
- On a quarterly basis, FCF Margin changed N/A year-over-year to 1530.2% in Q2 2025; TTM through Jun 2026 was 5069.2%, a 151860.0% increase from a year earlier, with the FY2025 full-year figure at 6198.2%, changed N/A from the prior year.
- FCF Margin was 1530.2% for Q2 2025 at Mereo BioPharma, down from 678.9% in the prior quarter.
- Over five years, FCF Margin peaked at 86.16% in Q2 2023 and troughed at 1530.2% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -18,629.40% |
| 10 | Mereo BioPharma | 38.92 Mn | 38.92 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -1,530.20% |
| Dec 31, 2023 | -678.90% |
| Jun 30, 2023 | -86.16% |